CN116390951A - Pd-l1结合剂及其用途 - Google Patents

Pd-l1结合剂及其用途 Download PDF

Info

Publication number
CN116390951A
CN116390951A CN202180067676.0A CN202180067676A CN116390951A CN 116390951 A CN116390951 A CN 116390951A CN 202180067676 A CN202180067676 A CN 202180067676A CN 116390951 A CN116390951 A CN 116390951A
Authority
CN
China
Prior art keywords
seq
amino acid
acid sequence
antibody
sequence shown
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180067676.0A
Other languages
English (en)
Chinese (zh)
Inventor
布莱恩·格拉泽
邦妮·哈默
西玛·坎塔克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exelixis Inc
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of CN116390951A publication Critical patent/CN116390951A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN202180067676.0A 2020-08-04 2021-08-03 Pd-l1结合剂及其用途 Pending CN116390951A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063061109P 2020-08-04 2020-08-04
US63/061,109 2020-08-04
PCT/US2021/044330 WO2022031695A1 (en) 2020-08-04 2021-08-03 Pd-l1 binding agents and uses thereof

Publications (1)

Publication Number Publication Date
CN116390951A true CN116390951A (zh) 2023-07-04

Family

ID=80118473

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180067676.0A Pending CN116390951A (zh) 2020-08-04 2021-08-03 Pd-l1结合剂及其用途

Country Status (7)

Country Link
US (1) US20230303699A1 (https=)
EP (1) EP4192884A4 (https=)
JP (1) JP7854423B2 (https=)
CN (1) CN116390951A (https=)
AU (1) AU2021322183A1 (https=)
CA (1) CA3187850A1 (https=)
WO (1) WO2022031695A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116390939A (zh) * 2020-08-04 2023-07-04 埃克塞里艾克西斯公司 多重特异性结合剂及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8362325B2 (en) * 2007-10-03 2013-01-29 Ceres, Inc. Nucleotide sequences and corresponding polypeptides conferring modulated plant characteristics
PE20110385A1 (es) * 2008-07-18 2011-06-22 Bristol Myers Squibb Co Anticuerpo de dominio (dab) que se une a cd28 y no reacciona en forma cruzada con ctla4
BR112014002716A2 (pt) * 2011-08-05 2017-06-13 Genentech Inc anticorpos anti-poliubiquitina e métodos de uso
MA40513A (fr) * 2014-08-12 2017-06-21 Novartis Ag Conjugués médicament-anticorps anti-cdh6
CA3007135A1 (en) * 2016-03-23 2017-09-28 Mabspace Biosciences (Suzhou) Co., Ltd Novel anti-pd-l1 antibodies
US20190106494A1 (en) * 2016-06-13 2019-04-11 Askgene Pharma Inc. PD-L1 Specific Monoclonal Antibodies for Disease Treatment and Diagnosis
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
WO2018005682A2 (en) 2016-06-29 2018-01-04 Checkpoint Therapeutics, Inc. Pd-l1-specific antibodies and methods of using the same
DK3592769T3 (da) 2017-03-09 2024-08-12 Genmab As Antistoffer mod pd-l1
SG10202110182PA (en) * 2017-03-15 2021-10-28 Silverback Therapeutics Inc Benzazepine compounds, conjugates, and uses thereof
EP3612565A4 (en) 2017-04-18 2021-06-16 R-Pharm Overseas, Inc. ANTI-PD-L1 ANTIBODIES AND USES THEREOF
US20210363265A1 (en) * 2017-08-24 2021-11-25 Invenra Inc. Multivalent receptor-clustering agonist antibody constructs
CA3080120C (en) * 2017-10-27 2023-11-21 New York University Anti-galectin-9 antibodies and uses thereof
EP3732203A4 (en) * 2017-12-28 2021-12-15 Nanjing Legend Biotech Co., Ltd. ANTIBODIES AND THEIR VARIANTS DIRECTED AGAINST PD-L1
CA3095076A1 (en) 2018-03-29 2019-10-03 Adagene Inc. Anti-pd-l1 antibodies and use thereof

Also Published As

Publication number Publication date
US20230303699A1 (en) 2023-09-28
AU2021322183A1 (en) 2023-03-02
WO2022031695A1 (en) 2022-02-10
EP4192884A1 (en) 2023-06-14
JP7854423B2 (ja) 2026-05-01
CA3187850A1 (en) 2022-02-10
JP2023536630A (ja) 2023-08-28
EP4192884A4 (en) 2025-04-09

Similar Documents

Publication Publication Date Title
WO2021058000A1 (zh) 抗人Claudin18.2抗体及其应用
JP2021513331A (ja) 抗ｂ７−ｈ４抗体、その抗原結合断片及びその医薬用途
JP7840312B2 (ja) 多重特異性結合性作用剤およびその使用
US20250197502A1 (en) Multispecific binding agents and uses thereof
KR20240021162A (ko) Alpha 5 베타 1 인테그린 결합제 및 이의 용도
US20250326858A1 (en) 5t4 binding agents and uses thereof
CN116507639A (zh) Cd47结合剂及其用途
WO2023245021A2 (en) Multispecific binding agents that target cd25 and/or ctla4 and uses thereof
CN116390951A (zh) Pd-l1结合剂及其用途
CN118974098A (zh) 多重特异性结合剂及其用途
WO2025129132A1 (en) Multispecific binding agents that target ctla4 and/or cd25 and uses thereof
HK40121590A (zh) α5β1整合素结合剂及其用途
HK40110702A (zh) α5β1整合素结合剂及其用途
HK1210186A1 (en) Anti-h7cr antibodies

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination